Dulera is NOT Approved for COPD
Dulera (mometasone furoate/formoterol) is FDA-approved exclusively for asthma treatment in patients 5 years and older and should not be used for COPD. 1
Why This Matters
The FDA label explicitly states that Dulera is indicated only for "the twice-daily treatment of asthma" and makes no mention of COPD as an approved indication 1. Using medications off-label for COPD when approved alternatives exist increases medicolegal risk and may not provide optimal outcomes.
What to Use Instead for COPD
For COPD patients requiring ICS/LABA combination therapy, the evidence-based options include:
Approved ICS/LABA Combinations for COPD:
- Fluticasone propionate/salmeterol (Advair): The most extensively studied combination in COPD 2, 3, 4, 3
- Budesonide/formoterol (Symbicort): Also well-studied with comparable efficacy 3, 5
When to Use ICS/LABA in COPD:
ICS/LABA combinations should be reserved for specific COPD patients:
- FEV1 <50% predicted (or <60% for some formulations) AND
- ≥2 exacerbations per year despite appropriate bronchodilator therapy 2
- OR patients with asthma-COPD overlap syndrome (ACOS) 2
Dosing for Approved Alternatives:
Fluticasone/salmeterol for COPD:
- 250/50 mcg: 1 inhalation twice daily 6, 7, 8
- 500/50 mcg: 1 inhalation twice daily for more severe disease 9, 10
Budesonide/formoterol for COPD:
- 160/4.5 mcg: 2 inhalations twice daily 5
Critical Safety Considerations
Pneumonia risk increases with ICS use in COPD - reported in 5-9% of patients on ICS/LABA combinations versus 1-4% on LABA alone 3, 6, 8. This risk must be weighed against exacerbation reduction benefits.
Lower ICS doses may provide similar efficacy with reduced pneumonia risk. Studies show 100-250 mcg fluticasone equivalent doses can be as effective as higher doses while reducing adverse events 6, 5.
First-Line COPD Treatment
Before considering ICS/LABA combinations, ensure patients are optimized on:
- LABA/LAMA combinations (preferred for most symptomatic COPD patients) 2, 3
- Single long-acting bronchodilators for less severe disease
ICS should only be added when patients remain symptomatic or continue having exacerbations despite optimal bronchodilator therapy 2, 3, 4.